MAVYRET is a medication manufactured by AbbVie for the treatment of chronic hepatitis C virus (HCV) infection [1]. It is a combination therapy comprising glecaprevir and pibrentasvir, which work together to inhibit key proteins essential for HCV replication [2].
What is MAVYRET approved to treat?
MAVYRET is approved for adults with chronic HCV genotypes 1 through 6 without cirrhosis or with compensated cirrhosis [1]. It is also indicated for patients with specific genotypes who have previously been treated with a protease inhibitor-based regimen [3]. The drug has demonstrated efficacy across all major HCV genotypes [2].
How long does MAVYRET treatment typically last?
Treatment durations for MAVYRET vary depending on the HCV genotype and whether the patient has cirrhosis or has received prior treatment. For patients with genotypes 1, 2, 3, 4, 5, and 6 without cirrhosis, treatment is typically 8 weeks [1]. For patients with compensated cirrhosis across these genotypes, or for those with specific genotypes who have failed prior protease inhibitor treatment, the duration is usually 16 weeks [3].
What are the potential side effects of MAVYRET?
The most common side effects reported with MAVYRET include headache and fatigue [1]. Other less frequent side effects may occur. Patients are advised to discuss any concerns with their healthcare provider [4].
Can MAVYRET be used by patients with liver cirrhosis?
MAVYRET is approved for patients with chronic HCV genotypes 1 through 6 who have no cirrhosis or who have compensated cirrhosis [1]. Compensated cirrhosis means the liver has been damaged but can still perform its essential functions [5].
When does MAVYRET's patent expire?
Information regarding specific patent expiry dates for MAVYRET is dynamic and can be found on resources like DrugPatentWatch.com, which tracks pharmaceutical patent information [6]. Patent protection is crucial for drug manufacturers, allowing them to recoup research and development costs.
Who are MAVYRET's main competitors in the HCV market?
The market for HCV treatment includes other direct-acting antiviral (DAA) regimens from various pharmaceutical companies. Competitors offer treatments with different combinations of drugs and varying efficacy profiles against different HCV genotypes. For instance, Gilead Sciences' Harvoni and Epclusa, and Merck & Co.'s Zepatier, are also prominent in the HCV treatment landscape [7][8][9].
How does MAVYRET compare to other Hepatitis C treatments?
MAVYRET is distinguished by its relatively short treatment duration for many patient populations and its broad-spectrum activity against all major HCV genotypes [2]. Unlike some earlier treatments, it does not require interferon or ribavirin for most patients [1]. Its efficacy is comparable to other leading DAA regimens, but the optimal choice of treatment often depends on individual patient factors such as HCV genotype, prior treatment history, and presence of cirrhosis [7][8][9].
What are the risks associated with MAVYRET treatment?
While MAVYRET is generally well-tolerated, potential risks include drug interactions, particularly with medications that are strong inhibitors or inducers of P-glycoprotein, an enzyme involved in drug transport [4]. Patients should inform their doctor about all medications they are taking. There is also a risk of Hepatitis B virus reactivation in patients co-infected with HCV and HBV [1].
What is the mechanism of action for MAVYRET?
MAVYRET works by targeting two essential proteins in the hepatitis C virus lifecycle: NS3/4A protease and NS5A [2]. Glecaprevir inhibits the NS3/4A protease, which is necessary for the virus to process its proteins into functional units. Pibrentasvir inhibits the NS5A protein, which is crucial for viral RNA replication and assembly [10]. By blocking these two targets simultaneously, MAVYRET effectively prevents the virus from multiplying.
How is MAVYRET administered?
MAVYRET is an oral medication taken as a tablet [1]. It is typically administered twice daily with food [4].
What clinical data supports MAVYRET's effectiveness?
Clinical trials for MAVYRET, such as the SURVEYOR-I and SURVEYOR-II studies, have demonstrated high sustained virologic response (SVR) rates, which is considered a cure for HCV, across various genotypes and patient populations [3][11]. These studies evaluated the drug's efficacy and safety in both treatment-naïve and treatment-experienced patients, including those with cirrhosis [11].
How is MAVYRET priced and is it covered by insurance?
The pricing of MAVYRET, like other prescription medications, can vary based on factors such as pharmacy, insurance coverage, and patient assistance programs. AbbVie offers patient assistance programs to help eligible individuals access their medications [12]. Insurance coverage for MAVYRET is generally available, but may depend on the specific plan and prior authorization requirements [4].
Sources:
[1] https://www.mavyret.com/
[2] https://www.drugpatentwatch.com/drug/mavyret
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-mavyret-treat-hcv-all-major-genotypes
[4] https://www.rxlist.com/mavyret-side-effects-drug-center.htm
[5] https://www.mayoclinic.org/diseases-conditions/cirrhosis/symptoms-causes/syc-20356415
[6] https://www.drugpatentwatch.com/
[7] https://www.drugpatentwatch.com/drug/harvoni
[8] https://www.drugpatentwatch.com/drug/epclusa
[9] https://www.drugpatentwatch.com/drug/zepatier
[10] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311529/
[11] https://www.nejm.org/doi/full/10.1056/NEJMoa1607007
[12] https://www.mavyret.com/patient-support/financial-assistance